Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NKTR Nektar Therapeutics

Pre-Mkt 11-10 08:02:14 EST

37.83

+0.57

+1.52%

盘前36.91

-0.92-2.42%

07:54 EST

High38.30	Low36.62	Vol684.34K
Open37.27	D1 Closing37.26	Amplitude4.51%
Mkt Cap1.29B	Tradable Cap1.27B	Total Shares34.14M
T/O25.81M	T/O Rate2.04%	Tradable Shares33.55M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NKTR","market":"US","secType":"STK","nameCN":"Nektar Therapeutics","latestPrice":37.825,"timestamp":1794258000000,"preClose":37.26,"halted":0,"volume":684337,"hourTrading":{"tag":"盘前","latestPrice":36.91,"preClose":37.825,"latestTime":"07:54 EST","volume":5,"amount":182.966785,"timestamp":1794315299665,"change":-0.915,"changeRate":-0.02419,"amplitude":0},"delay":0,"changeRate":0.015163714439076888,"floatShares":33545280,"shares":34142994,"eps":-6.468026,"marketStatus":"Pre-Mkt","change":0.565,"latestTime":"11-10 08:02:14 EST","open":37.27,"high":38.3,"low":36.6201,"amount":25812041.95384,"amplitude":0.045086,"askPrice":38.49,"askSize":39,"bidPrice":36.9,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-6.468026,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1794321000000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":37.825,"preHourTrading":{"tag":"盘前","latestPrice":36.91,"preClose":37.825,"latestTime":"07:54 EST","volume":5,"amount":182.966785,"timestamp":1794315299665,"change":-0.915,"changeRate":-0.02419,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":37.825,"preClose":37.825,"latestTime":"19:49 EST","volume":87610,"amount":3313848.925,"timestamp":1794271742338,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.0815487612353356,"impliedVol":0.9279,"impliedVolPercentile":0.776},"requestUrl":"/m/hq/s/NKTR","defaultTab":"news","newsList":[{"id":"1152267692","title":"Earning Preview: Nektar Therapeutics this quarter’s revenue is expected to increase by 2.24%, and institutional views are mostly bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1152267692","media":"Earnings Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1152267692?lang=en_us&edition=fundamental","pubTime":"2026-11-05 11:03","pubTimestamp":1793847811,"startTime":"0","endTime":"0","summary":"Abstract Nektar Therapeutics will release quarterly results on November 12, 2026 Post-Mkt; consensus points to revenue of 10.27 million US dollars and adjusted EPS of -2.07, with focus on royalty and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Earning Preview: Nektar Therapeutics this quarter’s revenue is expected to increase by 2.24%, and institutional views are mostly bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681847185","title":"What Nektar Therapeutics Stock's Late Stage Eczema Drug Progress Means For Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2681847185","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681847185?lang=en_us&edition=fundamental","pubTime":"2026-11-08 17:35","pubTimestamp":1794130533,"startTime":"0","endTime":"0","summary":"SSasha JovanovicNovember 8, 2026","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/what-nektar-therapeutics-stocks-late-stage-eczema-drug-progr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/what-nektar-therapeutics-stocks-late-stage-eczema-drug-progr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","PRGS","LU2065732104.USD","BK4097","NKTR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681811078","title":"Nektar Therapeutics (NKTR) Draws Fresh Eczema Buzz Following A 72% Undervalued Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2681811078","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681811078?lang=en_us&edition=fundamental","pubTime":"2026-11-07 16:40","pubTimestamp":1794040812,"startTime":"0","endTime":"0","summary":"SSasha JovanovicNovember 7, 2026","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/nektar-therapeutics-nktr-draws-fresh-eczema-buzz-following-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/nektar-therapeutics-nktr-draws-fresh-eczema-buzz-following-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NKTR","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681785501","title":"Nektar Therapeutics Defendants Move to Dismiss Securities Fraud Lawsuit Over REZPEG Alopecia Trial Disclosures","url":"https://stock-news.laohu8.com/highlight/detail?id=2681785501","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681785501?lang=en_us&edition=fundamental","pubTime":"2026-11-06 16:27","pubTimestamp":1793953667,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics ($NKTR) and three of its executives have asked a federal court to dismiss a securities fraud lawsuit that centers on the compan...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/nektar-therapeutics-defendants-move-to-dismiss-securities-fraud-lawsuit-over-rezpeg-alopecia-trial-disclosures?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/nektar-therapeutics-defendants-move-to-dismiss-securities-fraud-lawsuit-over-rezpeg-alopecia-trial-disclosures?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTR","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678081481","title":"Nektar Therapeutics Schedules Third-Quarter Results Release","url":"https://stock-news.laohu8.com/highlight/detail?id=2678081481","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678081481?lang=en_us&edition=fundamental","pubTime":"2026-10-28 06:00","pubTimestamp":1793138420,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics schedules third-quarter results releaseNektar Therapeutics will report third-quarter results Nov. 12, 2026, after U.S. markets close.CEO Howard Robin will host a results conference","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261027:nNDL7ZNpbG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677972485","title":"Nektar Therapeutics Grants 45,750 Stock Options, 2,775 RSUs to 16 New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2677972485","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677972485?lang=en_us&edition=fundamental","pubTime":"2026-10-24 04:15","pubTimestamp":1792786539,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics Grants 45,750 Stock Options, 2,775 RSUs to 16 New EmployeesNektar Therapeutics granted 45,750 non-qualified stock options and 2,775 restricted stock units on October 20, 2026.The a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261023:nNDL7d3Rdb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677972104","title":"Nektar Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2677972104","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677972104?lang=en_us&edition=fundamental","pubTime":"2026-10-24 04:15","pubTimestamp":1792786500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261023:nTUA9XCND4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674446803","title":"Nektar Therapeutics Initiated at Neutral by UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2674446803","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674446803?lang=en_us&edition=fundamental","pubTime":"2026-10-12 22:00","pubTimestamp":1791813600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NKTR/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674966872","title":"UBS Initiates Coverage on Nektar Therapeutics With Neutral Rating, $53 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2674966872","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674966872?lang=en_us&edition=fundamental","pubTime":"2026-10-12 19:38","pubTimestamp":1791805096,"startTime":"0","endTime":"0","summary":"UBS Initiates Coverage on Nektar Therapeutics With Neutral Rating, $53 Price Target","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674879609","title":"Leerink Partners Initiates Nektar Therapeutics at Outperform, $130 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2674879609","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674879609?lang=en_us&edition=fundamental","pubTime":"2026-10-12 18:14","pubTimestamp":1791800068,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics (NKTR) has an average rating of buy and mean price target of $141.40, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HELS","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674841786","title":"Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and Nektar Therapeutics (NKTR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2674841786","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674841786?lang=en_us&edition=fundamental","pubTime":"2026-10-12 07:01","pubTimestamp":1791759679,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Insmed (INSM) and Nektar Therapeutics (NKTR) with bu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-insmed-insm-and-nektar-therapeutics-nktr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-insmed-insm-and-nektar-therapeutics-nktr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","LU0053671581.USD","BK4137","BK4581","BK4007","HCSG","LU0889565916.HKD","BK4588","XLV","NKTR","LABU","LU0109394709.USD","LU0128526141.USD","XBI","INSM","BK4585","BK4139","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674685697","title":"Nektar Therapeutics Initiated at Market Perform by Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2674685697","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674685697?lang=en_us&edition=fundamental","pubTime":"2026-10-09 19:09","pubTimestamp":1791544140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NKTR/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1804176565.USD","RJF","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU2265009873.SGD","LU0971096721.USD","NKTR","LU1363072403.SGD","BK4585","BK4007","BK4139","BK4127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674343048","title":"Lawsuit Win Could Be A Game Changer For Nektar Therapeutics (NKTR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2674343048","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674343048?lang=en_us&edition=fundamental","pubTime":"2026-10-09 14:45","pubTimestamp":1791528314,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics reported past long term Phase 2b data for rezpegaldesleukin in alopecia areata and atopic dermatitis, along with a $115 million legal win over Eli Lilly that removes a long running contract dispute overhang.\nThe same rezpegaldesleukin data set highlights durable responses with less frequent dosing schedules, which directly affects future trial design, treatment positioning, and potential development costs.\nWe will now look at how Nektar Therapeutics' investment narrative...","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/lawsuit-win-could-be-a-game-changer-for-nektar-therapeutics","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/lawsuit-win-could-be-a-game-changer-for-nektar-therapeutics","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","NKTR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674100059","title":"Nektar initiated with a Market Perform at Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2674100059","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674100059?lang=en_us&edition=fundamental","pubTime":"2026-10-09 04:10","pubTimestamp":1791490246,"startTime":"0","endTime":"0","summary":"Raymond James initiated coverage of Nektar (NKTR) with a Market Perform rating and no price target Treg modulation is “a scientifically compelling ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nektar-initiated-with-a-market-perform-at-raymond-james-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nektar-initiated-with-a-market-perform-at-raymond-james-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IE00B64PRP62.GBP","LU1363072403.SGD","BK4588","LU0971096721.USD","NKTR","LU2265009873.SGD","RJF","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4007","LU1804176565.USD","BK4127","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672671402","title":"B. Riley Securities Keeps Their Buy Rating on Nektar Therapeutics (NKTR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2672671402","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672671402?lang=en_us&edition=fundamental","pubTime":"2026-10-02 20:55","pubTimestamp":1790945729,"startTime":"0","endTime":"0","summary":"In a report released today, from B. Riley Securities maintained a Buy rating on Nektar Therapeutics, with a price target of $150.00. In addition to...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/b-riley-securities-keeps-their-buy-rating-on-nektar-therapeutics-nktr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/b-riley-securities-keeps-their-buy-rating-on-nektar-therapeutics-nktr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672719074","title":"Nektar Therapeutics Price Target Maintained with a $185.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2672719074","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672719074?lang=en_us&edition=fundamental","pubTime":"2026-10-02 19:39","pubTimestamp":1790941140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NKTR/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672168177","title":"Nektar selloff yesterday overdone, says H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2672168177","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672168177?lang=en_us&edition=fundamental","pubTime":"2026-10-02 18:15","pubTimestamp":1790936148,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Arthur He views the 22% pullback yesterday in shares of Nektar (NKTR) as overdone. The company presented 52-week treatment ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nektar-selloff-yesterday-overdone-says-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nektar-selloff-yesterday-overdone-says-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162160441","title":"Movement Alert｜Nektar Therapeutics Falls 19.63% in Regular Trading, Trading at $48.81","url":"https://stock-news.laohu8.com/highlight/detail?id=1162160441","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162160441?lang=en_us&edition=fundamental","pubTime":"2026-10-02 02:41","pubTimestamp":1790880064,"startTime":"0","endTime":"0","summary":"On October 1, Nektar Therapeutics fell 19.63% in regular trading, trading at $48.81 USD/share, with Turnover of $206 million.Within the Pharmacy sector where Nektar Therapeutics belongs, individual...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672323761","title":"Nektar selloff after rezpegaldesleukin data ‘unwarranted,’ says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2672323761","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672323761?lang=en_us&edition=fundamental","pubTime":"2026-10-02 02:25","pubTimestamp":1790879111,"startTime":"0","endTime":"0","summary":"Jefferies analyst Roger Song sees the selloff in shares of Nektar (NKTR) following updated rezpegaldesleukin data “unwarranted.” The off-treatment ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nektar-selloff-after-rezpegaldesleukin-data-unwarranted-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nektar-selloff-after-rezpegaldesleukin-data-unwarranted-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672766371","title":"William Blair says rezpeg data a positive for Nektar","url":"https://stock-news.laohu8.com/highlight/detail?id=2672766371","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672766371?lang=en_us&edition=fundamental","pubTime":"2026-10-02 00:15","pubTimestamp":1790871334,"startTime":"0","endTime":"0","summary":"William Blair analyst Andy Hsieh maintained an Outperform rating on Nektar (NKTR) Therapeutics following updated rezpegaldesleukin, or rezpeg, data...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/william-blair-says-rezpeg-data-a-positive-for-nektar-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/william-blair-says-rezpeg-data-a-positive-for-nektar-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nektar.com","stockEarnings":[{"period":"1week","weight":0.0237},{"period":"1month","weight":-0.0812},{"period":"3month","weight":-0.499},{"period":"6month","weight":-0.502},{"period":"1year","weight":-0.3242},{"period":"ytd","weight":-0.1054}],"compareEarnings":[{"period":"1week","weight":0.0008},{"period":"1month","weight":-0.0332},{"period":"3month","weight":-0.0232},{"period":"6month","weight":0.014},{"period":"1year","weight":0.1218},{"period":"ytd","weight":0.1038}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc.  The company was incorporated in 1990 and is headquartered in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.53125,"avgChangeRate":0.03787},{"month":2,"riseRate":0.53125,"avgChangeRate":0.029488},{"month":3,"riseRate":0.40625,"avgChangeRate":-0.000642},{"month":4,"riseRate":0.46875,"avgChangeRate":0.016904},{"month":5,"riseRate":0.34375,"avgChangeRate":-0.004399},{"month":6,"riseRate":0.424242,"avgChangeRate":0.026471},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.018591},{"month":8,"riseRate":0.484848,"avgChangeRate":0.043831},{"month":9,"riseRate":0.484848,"avgChangeRate":0.036592},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.033431},{"month":11,"riseRate":0.666667,"avgChangeRate":0.083673},{"month":12,"riseRate":0.59375,"avgChangeRate":0.015542}],"exchange":"NASDAQ","name":"Nektar Therapeutics","nameEN":"Nektar Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nektar Therapeutics(NKTR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nektar Therapeutics,NKTR,Nektar Therapeutics股票,Nektar Therapeutics股票老虎,Nektar Therapeutics股票老虎国际,Nektar Therapeutics行情,Nektar Therapeutics股票行情,Nektar Therapeutics股价,Nektar Therapeutics股市,Nektar Therapeutics股票价格,Nektar Therapeutics股票交易,Nektar Therapeutics股票购买,Nektar Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nektar Therapeutics(NKTR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}